Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. (ANAB) reports corporate governance changes effective April 1, 2023. The report covers the resignation of a Class II director and the subsequent appointment of a new director to the Board.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel and compensation arrangements.
Material Changes
- Director Resignation: Laura J. Hamill resigned as a Class II director effective April 1, 2023. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: On April 3, 2023, the Board appointed Rita Jain, M.D., as a Class II director and member of the Compensation Committee, effective immediately.
Compensation and Governance Details
In connection with Dr. Jain's appointment, the Board granted the following compensation packages subject to continued service:
- Annual Retainer (Pro Rata):
- Stock option to purchase 8,015 shares at the closing price on April 3, 2023, vesting monthly in full by January 6, 2024.
- 3,234 restricted stock units (RSUs) vesting in full at the 2024 annual meeting.
- Additional Grant:
- Stock option to purchase 10,600 shares at the closing price on April 3, 2023, vesting monthly over three years.
- 3,900 RSUs vesting over a three-year period (one-third annually starting June 15, 2024).
Dr. Jain has entered into the Company's standard indemnification agreement. No family relationships or undisclosed material interests were reported.
Investor Verification Checklist
- Verify the current composition of the Board of Directors and the Compensation Committee following Dr. Jain's appointment.
- Review the vesting schedules for the 18,615 total stock options and 7,134 total RSUs granted to Dr. Jain.
- Confirm the closing sale price of ANAB common stock on April 3, 2023, to determine the exercise price for the granted options.
- Check for any subsequent filings regarding the status of the Class II director seat previously held by Ms. Hamill.